Acromegaly Program in Pharmaceutical Benefits Scheme (PBS) 012-18051100

This document outlines details of PBS-subsidised pasireotide and pegvisomant for patients with acromegaly.

Acromegaly and listing dates

Acromegaly is a condition caused by excessive growth hormone.

Listing dates:

• pasireotide - 1 September 2016
• pegvisomant - 1 September 2017

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

• application forms
• contact details
• restriction and item codes
• the PBS schedule
• Services Australia website link

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs